Comparative study between the effect of the peroxisome proliferator activated receptor-α ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5′-AMP-activated protein kinase-α1 in high-fat fed rats

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 10, 2009, Pages 1339-1346

  Kamal Motawi, Tarek M ^a   Hashem, Reem M ^b   Rashed, Laila A ^c   Abd El Razek, Sabry M ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Beni Suef University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

AMPK 1; CPT 1; Diabetes mellitus; Fenofibrate; PPAR

Indexed keywords

AMPK ALPHA1 ENZYME; CHOLESTEROL; FATTY ACID; FENOFIBRATE; GLUCOSE; MESSENGER RNA; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CARNITINE PALMITOYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; UNSATURATED FATTY ACID;

ARTICLE; COLORIMETRY; DIET RESTRICTION; DRUG ACTIVITY; ENZYME ACTIVATION; FATTY ACID OXIDATION; LIPID DIET; LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; ANIMAL; BLOOD; BODY WEIGHT; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; ELEMENTAL DIET; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; OBESITY; RANDOMIZATION; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARNITINE O-PALMITOYLTRANSFERASE; CHOLESTEROL; FATTY ACIDS, UNSATURATED; FOOD, FORMULATED; GENE EXPRESSION; LIVER; MALE; MUSCLE, SKELETAL; OBESITY; PPAR ALPHA; PROCETOFEN; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; TRIGLYCERIDES;

EID: 74949113991     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.10.0010     Document Type: Article

References (44)

1. Friedman JM. Obesity in the new millennium. Nature 2000; 404: 632-634.
2. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
3. Hellström PMet al. Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. Br J Nutr 2004; 92(Suppl. 1): S47-S57.
4. Carling D. The role of the AMP-activated protein kinase in the regulation of energy homeostasis. Novartis Found Symp 2007; 286: 72-81; discussion 81-85, 162-163, 196-203.
5. Stapleton D et al. AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett 1997; 409: 452-456.
6. Woods A et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 2000; 20: 6704-6711.
7. Lev S et al. Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions. Nature (London) 1995; 376: 737-745.
8. Barnes BR et al. Isoform-specific regulation of 5′ AMPactivated protein kinase in skeletal muscle from obese Zucker (fa/fa) rats in response to contraction. Diabetes 2002; 51: 2703-2708.
9. Rutter GA et al. Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 2003; 375: 1-16.
10. Thomson DM et al. AMP-activated protein kinase phosphorylates transcription factors of the CREB family. J Appl Physiol 2008; 104: 429-438.
11. Hardie DG et al. AMP-activated protein kinase-development of the energy sensor concept. J Physiol 2006; 574(Pt 1): 7-15.
12. Saha AK, Ruderman NB. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem 2003; 253: 65-70.
13. Cignarella A et al. Hypolipidemic therapy for the metabolic syndrome. Pharmacol Res 2006; 53: 492-500.
14. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
15. Misra P. AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin Ther Targets 2008; 12: 91-100.
16. Dobrzyn A et al. Polyunsaturated fatty acids do not activate AMP-activated protein kinase in mouse tissues. Biochem Biophys Res Commun 2005; 332: 892-896.
17. Suchankova G et al. Dietary polyunsaturated fatty acids enhance hepatic AMP-activated protein kinase activity in rats. Biochem Biophys Res Commun 2005; 326: 851-858.
18. Mancini FP et al. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 2001; 491: 154-158.
19. Naderali EK et al. Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats. Atherosclerosis 2004; 177: 307-312.
20. Duncombe WG. The colorimetric micro-determination of longchain fatty acids. Biochem J 1963; 88: 7-10.
21. Santomauro Júnior AC et al. Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome. Arq Bras Endocrinol Metabol 2008; 52: 120-125.
22. Braissant O et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-366.
23. Willson TM et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550.
24. Cho MC et al. Peroxisome proliferator-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res 2008; 2008: 679137.
25. Yu S et al. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 2003; 3: 561-572.
26. Morash AJ et al. Effects of dietary fatty acid composition on the regulation of carnitine palmitoyltransferase (CPT) I in rainbow trout (Oncorhynchus mykiss). Comp Biochem Physiol B Biochem Mol Biol 2009; 152: 85-93.
27. Bai XP et al. Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity. Zhonghua Yi Xue Za Zhi 2008; 88: 268-270.
28. Yang J et al. Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice. Biochem Biophys Res Commun 2008; 370: 248-253.
29. Lawrence VJ, Kopelman PG. Medical consequences of obesity. Clin Dermatol 2004; 22: 296-302.
30. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
31. Hashem RM et al. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur J Gastroenterol Hepatol 2008; 10: 995-1001.
32. Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995; 80: 1584-1590.
33. Blaschke F et al. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26: 28-40.
34. DeFronzo RA et al. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368.
35. Shulman GI et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 322: 223-228.
36. DeFronzo RA et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985; 76: 149-155.
37. Dohm GL et al. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest 1988; 82: 486-494.
38. Oatey PB et al. GLUT4 vesicle dynamics in living 3T3 L1 adipocytes visualized with green-fluorescent protein. Biochem J 1997; 327: 637-642.
39. Ryder JW et al. Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle. Acta Physiol Scand 2001; 171: 249-257.
40. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998; 49: 235-261.
41. Koistinen HA et al. 5-Amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes 2003; 52: 1066-1072.
42. Kurth-Kraczek EJ et al. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999; 48: 1667-1671.
43. Moore MC, Cherrington AD. The nerves, the liver, and the route of feeding: an integrated response to nutrient delivery. Nutrition 1996; 12: 282-284.
44. Burcelin R et al. GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization. J Clin Invest 2003; 111: 1555-1562.